Despite prophylaxis with immunosuppressive agents or a variety of other approaches, many
patients suffer from acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic …

Graft versus host disease (GVHD) remains a major cause of morbidity and mortality
following allogeneic hematopoietic stem-cell transplantation (HSCT). Despite the use of …

Despite major improvements in allogeneic hematopoietic cell transplantation over the past
decades, corticosteroid-refractory (SR) acute (a) and chronic (c) graft-versus-host disease …

Steroid refractory chronic graft-versus-host disease (cGVHD) is associated with a significant
morbidity and mortality. Although first-line treatment of cGVHD is based on controlled trials …

Refractory chronic GVHD (cGVHD) is an important complication after allogeneic
hematopoietic SCT and is prognostic of poor outcome. MSCs are involved in tissue repair …

There is no consistently effective therapy for patients with steroid-refractory acute graft-
versus-host disease (GVHD). Various alternative approaches have been tested, including …

We previously reported that patients with fibrotic, chronic graft-versus-host disease (cGVHD)
have antibodies activating the platelet-derived growth factor receptor pathway. Because this …

Acute graft-versus-host disease (aGVHD) is the primary limitation of allogeneic
hematopoietic cell transplantation. Corticosteroids remain the standard initial therapy, yet …

Steroid‐refractory (SR) acute graft‐versus‐host disease (aGVHD) is one of the leading
causes of early mortality after allogeneic hematopoietic stem cell transplantation (allo …

We conducted a double-blind, randomized multicenter trial to determine whether the
addition of mycophenolate mofetil (MMF) improves the efficacy of initial systemic treatment of …